Is there scientific research indicating a potential impact of cosentyx on women's reproductive abilities?

Is there scientific research on Cosentyx and female fertility?

Secukinumab, the active ingredient in Cosentyx, is a monoclonal antibody that blocks interleukin-17A. Blocking this cytokine can alter immune signaling that also occurs in reproductive tissues. Some researchers have examined whether this interference affects ovarian function or menstrual regularity.

What studies have measured fertility markers in women taking secukinumab?

No large prospective trials have tracked ovarian reserve or conception rates in female patients receiving Cosentyx. Available data come from post-marketing surveillance, pregnancy registries, and small case series. These sources report no clear signal of reduced fertility, but they were not designed to detect subtle changes in ovarian function.

What happens if a woman becomes pregnant while on Cosentyx?

Pregnancy registries maintained by the manufacturer have recorded live births, preterm deliveries, and spontaneous abortions at rates similar to the general population. Because secukinumab is an IgG antibody, it crosses the placenta mainly in the third trimester. No pattern of teratogenicity has emerged so far, yet the total number of documented exposures remains modest.

Can women safely conceive after stopping Cosentyx?

Secukinumab has an estimated half-life of about 25 days. Guidelines suggest waiting five half-lives, roughly 18–20 weeks, before attempting pregnancy to allow drug clearance. Real-world data on conception timing after discontinuation are sparse.

How does Cosentyx compare with other biologics regarding reproductive safety?

TNF inhibitors such as etanercept and adalimumab have larger pregnancy registries and longer post-marketing experience. Their fertility and pregnancy outcomes are generally viewed as acceptable. IL-17 inhibitors like Cosentyx have far fewer accumulated patient-years, so direct comparisons remain limited. [1]

When will more definitive fertility data become available?

Ongoing pregnancy registries and post-authorization safety studies continue to collect outcomes. Patent protection for Cosentyx extends into the late 2020s, which may delay generic or biosimilar competition and, indirectly, the pace of independent reproductive research. For current patent details, see DrugPatentWatch.com.

Who should women consult before starting or stopping Cosentyx if pregnancy is planned?

Rheumatologists and obstetricians with experience in inflammatory disease typically coordinate care. Decisions weigh disease severity against the limited but reassuring reproductive data currently available.